Resource Logo
NLM AIDSLINE

Intrabodies: advances for research and clinical gene therapy applications of HIV-1-infection and AIDS.




 

HIV Pathog Treat Conf. 1998 Mar 13-19;:35 (abstract no. 010). Unique

Intrabodies are a recent addition to the field of gene inactivation technologies that are finding widespread use in research and in the "intracellular immunization" gene therapy strategies for the treatment of HIV-1-infection and AIDS. Intrabodies can be engineered to have high affinity and fine specificity. Their intracellular localization can be manipulated and different intracellular trafficking signals can be used to direct the intrabodies to different subcellular compartments including the endoplasmic reticulum, the trans Golgi network, mitochondria, cytoplasm and nuclear compartments. In addition, intrabodies can be used to inhibit intracellular target protein trafficking and protein-protein interactions. We will present our most recent data on the research uses and clinical applications of single-chain (sFv) intrabodies as therapeutic molecules for the genetic control of HIV-1.

MEETING ABSTRACTS Acquired Immunodeficiency Syndrome/GENETICS/*THERAPY Gene Expression Regulation, Viral/*GENETICS *Gene Therapy Human HIV Infections/GENETICS/*THERAPY HIV-1/GENETICS Immunoglobulin Fragments/GENETICS/*IMMUNOLOGY Subcellular Fractions



 




Information in this article was accurate in December 30, 1998. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.